| Date Filed | Type | Description |
| 02/09/2023 |
SC 13G/A
| Versant Venture Capital VI, L.P. reports a 19.4% stake in Century Therapeutics, Inc. |
| 01/13/2023 |
SC 13D/A
| Versant Venture Capital VI, L.P. reports a 0% stake in OYSTER POINT PHARMA, INC. |
| 05/09/2022 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 02/10/2022 |
SC 13G
| Versant Venture Capital VI, L.P. reports a 22.6% stake in Century Therapeutics, Inc. |
| 02/10/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 01/13/2022 |
SC 13D/A
| Versant Venture Capital VI, L.P. reports a 8.5% stake in OYSTER POINT PHARMA, INC. |
| 10/27/2021 |
SC 13D/A
| Versant Venture Capital VI, L.P. reports a 8.6% stake in OYSTER POINT PHARMA, INC. |
| 07/09/2021 |
SC 13D
| Versant Venture Capital VI, L.P. reports a 26.3% stake in Graphite Bio, Inc. |
| 07/08/2021 |
SC 13D
| Versant Venture Capital VI, L.P. reports a 15.3% stake in Monte Rosa Therapeutics, Inc. |
| 06/21/2021 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 05/24/2021 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 05/03/2021 |
SC 13D/A
| Versant Venture Capital VI, L.P. reports a 5.1% stake in Aligos Therapeutics, Inc. |
| 04/08/2021 |
SC 13D
| Versant Venture Capital VI, L.P. reports a 13.4% stake in LAVA THERAPEUTICS N.V. |
| 04/05/2021 |
SC 13D/A
| Versant Venture Capital VI, L.P. reports a 8.6% stake in OYSTER POINT PHARMA, INC. |
| 03/01/2021 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 02/12/2021 |
SC 13G/A
| Versant Venture Capital VI, L.P. reports a 2.2% stake in Akero Therapeutics, Inc. |
| 12/03/2020 |
SC 13D/A
| Versant Venture Capital VI, L.P. reports a 12% stake in Black Diamond Therapeutics, Inc. |
| 10/30/2020 |
SC 13D
| Versant Venture Capital VI, L.P. reports a 7.2% stake in Aligos Therapeutics, Inc. |
| 09/25/2020 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 08/21/2020 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 07/31/2020 |
SC 13G
| Versant Venture Capital VI, L.P. reports a 11.1% stake in Pandion Therapeutics, Inc. |
| 03/13/2020 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 02/14/2020 |
SC 13G/A
| Versant Venture Capital VI, L.P. reports a 12.8% stake in Akero Therapeutics, Inc. |
| 02/13/2020 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 11/14/2019 |
SC 13D
| Versant Venture Capital VI, L.P. reports a 12.4% stake in OYSTER POINT PHARMA, INC. |
| 07/05/2019 |
SC 13G
| Versant Venture Capital VI, L.P. reports a 14.7% stake in Akero Therapeutics, Inc. |